(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 420.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Crispr Therapeutics Ag's revenue in 2026 is $3,510,000.On average, 30 Wall Street analysts forecast CRSP's revenue for 2026 to be $3,058,188,026, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $10,179,242,338. On average, 26 Wall Street analysts forecast CRSP's revenue for 2027 to be $8,334,308,656, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $25,347,801,193.
In 2028, CRSP is forecast to generate $58,000,084,629 in revenue, with the lowest revenue forecast at $1,707,290,745 and the highest revenue forecast at $387,300,733,920.